$2.79+0.03 (+1.09%)
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
Evaxion A/S in the Healthcare sector is trading at $2.79 with a market capitalization of $25M. Wall Street consensus targets $11.25 (4 analysts), implying a +303.2% move over the next 12 months. The stock is currently near its 52-week low of $2.72, remaining 22.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0β | $7.49Mβ | $37,000 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$3.85Mβ | -$3.82Mβ | -$4.05Mβ | $3.02Mβ | -$4.34M |
| Net Income | -$3.73Mβ | -$3.63Mβ | -$5.92Mβ | $4.62Mβ | -$4.83M |
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based...